The Hindu Business Line : US co Generex in pact with Shreya Life for insulin spray

The US-based Generex Biotechnology Corporation has entered into a product licensing and distribution agreement with Shreya Life Sciences Pvt Ltd to market Generex Oral-lyn oral insulin spray product.

According to the company, this is the first non-injectible buccal insulin approved in India.

Discussions are on between both the companies for commercial launch of the product in India in early 2008.

Generex is a leader in drug delivery for metabolic diseases through the inner lining of the mouth. The company's proprietary oral insulin spray product - Oral-lyn - has recently received approval for importation and commercial marketing and sale in India for the treatment of diabetes. The product is administered orally by the company's proprietary device RapidMist. Shreya is the fourth largest distributor of insulin in the Indian market and has interests in both pharmaceutical and biopharmaceutical products in key therapeutic segments including cardiology, neuropathy, and diabetes. The company has business operations in India, Russia, the Commonwealth of Independent States and African countries.

Diabetic patients

According to the Diabetes Atlas 2007, there are approximately 40.8 million diagnosed patients with diabetes in India. There are also an estimated 35.9 million people who have pre-diabetic conditions which, if not treated, could lead to full-blown diabetes.

"We look forward to working with Shreya to offer a safe, simple, fast, flexible, familiar, convenient, and pain-free alternative to prandial insulin injections," a Generex official said.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page